European Medicines Agency update on ongoing benefit-risk review of Avandia, Avandamet and Avaglim

View source ↗

Summary

EMA provides an update on the ongoing benefit-risk review of the diabetes medicines Avandia, Avandamet, and Avaglim.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Avaglim (rosiglitazone)
• Avandamet (rosiglitazone/metformin)
• Avandia (rosiglitazone)